Maat Pharma SA

Maat Pharma operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 9.69, indicating significant reliance on debt financing. The company's liquidity position is characterized as medium risk, with a current ratio of 1.94, suggesting it can cover its short-term liabilities but with limited buffer. The company's cash and equivalents amount to EUR 9,709,000, which is insufficient to cover its long-term debt of EUR 17,440,000, resulting in a net cash position that is negative after subtracting total debt. Profitability metrics for Maat Pharma are severely negative, with a return on equity of -17.2657 and a return on assets of -0.6972, indicating that the company is not generating returns for its shareholders or effectively utilizing its assets. The company's operating income is negative at EUR -29,729,000, and its net income is also negative at EUR -31,061,000, reflecting substantial operational and financial losses. Maat Pharma's revenue is concentrated in a single business segment focused on microbiome therapy, with no disclosed geographic diversification in the provided data. The company's revenue for the latest period is EUR 4,524,000, which is significantly lower than the industry median for biotechnology firms, indicating a small market presence. The company's growth trajectory is constrained by its current financial position, with no disclosed revenue growth in the latest period and no specific outlook provided for the next fiscal year. The company's operating cash flow is negative at EUR -15,719,000, and its free cash flow is also negative at EUR -30,067,000, indicating that it is not generating sufficient cash from operations to sustain its activities or invest in growth. Maat Pharma faces significant financial risks, including a high debt-to-equity ratio and negative net cash position, which could limit its ability to fund operations or respond to market opportunities. The company's dilution risk is currently assessed as low, but its high debt levels and negative cash flows could necessitate future equity issuances, potentially diluting existing shareholders. The company's capital expenditures are minimal at EUR -608,000, suggesting limited investment in growth or expansion. Recent events for Maat Pharma include analyst price targets ranging from EUR 12.00 to EUR 19.00, with a mean recommendation of 1.33, indicating a generally positive outlook from analysts despite the company's current financial challenges. The company has not disclosed any recent filings or transcripts that would provide additional insight into its strategic direction or operational performance.